Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Burnett, Alan K
AffiliationInstitut Paoli-Calmettes, Marseille, France. firstname.lastname@example.org
MetadataShow full item record
AbstractPURPOSE: Evaluation of the safety and efficacy of arsenic trioxide in patients with myelodysplastic syndromes (MDS). PATIENTS AND METHODS: MDS patients diagnosed according to standard French-American-British criteria received a loading dose of 0.3 mg/kg per day of arsenic trioxide for 5 days followed by a maintenance dose of 0.25 mg/kg arsenic trioxide twice weekly for 15 weeks. Patients were divided into two cohorts: lower-risk MDS (International Prognostic Scoring System risk category low or intermediate 1) and higher-risk MDS (International Prognostic Scoring System risk category intermediate 2 or high). Modified International Working Group criteria were used for response evaluation. RESULTS: Of 115 patients enrolled and treated in the study, 67% of patients were transfusion dependent at baseline; median age was 68 years. Most treatment-related adverse events were mild to moderate. The overall rate of hematologic improvement (intent-to-treat) was 24 (19%) of 115, including one complete and one partial response in the higher-risk cohort. The hematologic response rates were 13 (26%) of 50 and 11 (17%) of 64 in patients with lower-risk and higher-risk MDS, respectively. Major responses were observed in all three hematologic lineages; 16% of RBC transfusion-dependent patients and 29% of platelet transfusion-dependent patients became transfusion independent. At data cut off, the median response duration was 3.4 months, with responses ongoing in nine patients. CONCLUSION: Arsenic trioxide treatment consisting of an initial loading dose followed by maintenance therapy has moderate activity in MDS, inducing hematologic responses in both lower- and higher-risk patients. This activity combined with a manageable adverse effect profile warrants the additional study of arsenic trioxide, particularly in combination therapy, for the treatment of patients with MDS.
CitationArsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. 2006, 24 (16):2465-71 J. Clin. Oncol.
JournalJournal of Clinical Oncology
- Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
- Authors: Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF
- Issue date: 2006 Jun 1
- Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.
- Authors: Zheng WL, Zhang GS, Xu YX, Shen JK, Dai CW, Pei MF
- Issue date: 2008 Feb
- Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
- Authors: Amadori S, Fenaux P, Ludwig H, O'dwyer M, Sanz M
- Issue date: 2005 Mar
- Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
- Authors: Beran M
- Issue date: 2000 Aug
- Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
- Authors: Roboz GJ, Ritchie EK, Curcio T, Samuel M, Provenzano J, Segovia J, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ
- Issue date: 2011 Apr